{"filing":{"accession_number":"0001193125-26-237832","cik":"0001750284","ticker":"OLMA","company_name":"Olema Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"olma-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm"},"events":[{"id":9004,"run_id":7903,"accession_number":"0001193125-26-237832","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Olema announced entry into a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 (Olema's KAT6 inhibitor) in combination with NUBEQA® (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer. This strategic partnership represents a material development for Olema's pipeline and commercial prospects.","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1477,"accession_number":"0001193125-26-237832","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Olema announced entry into a \"clinical trial collaboration and supply agreement\" with Bayer, a major pharmaceutical company. While this is a material partnership for a biopharmaceutical company, it does not fit cleanly into the M\u0026A taxonomy (ma_activity applies to acquisitions, dispositions, mergers, or changes of control). The agreement appears to be a strategic collaboration rather than a transaction that transfers material assets or control, making \"other_material\" the most appropriate classification for this significant but non-transactional corporate event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:09.030521+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1478,"accession_number":"0001193125-26-237832","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Olema announced a clinical collaboration agreement with Bayer to evaluate OP-3136 (Olema's KAT6 inhibitor) in combination with NUBEQA® (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer. While this represents a material partnership for a clinical-stage asset, it does not fit cleanly into the M\u0026A activity category (no acquisition, merger, or change of control) and is better classified as a material strategic collaboration that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:09.030521+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1477,"accession_number":"0001193125-26-237832","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Olema announced entry into a \"clinical trial collaboration and supply agreement\" with Bayer, a major pharmaceutical company. While this is a material partnership for a biopharmaceutical company, it does not fit cleanly into the M\u0026A taxonomy (ma_activity applies to acquisitions, dispositions, mergers, or changes of control). The agreement appears to be a strategic collaboration rather than a transaction that transfers material assets or control, making \"other_material\" the most appropriate classification for this significant but non-transactional corporate event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:09.030521+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-26"},{"id":1478,"accession_number":"0001193125-26-237832","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Olema announced a clinical collaboration agreement with Bayer to evaluate OP-3136 (Olema's KAT6 inhibitor) in combination with NUBEQA® (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer. While this represents a material partnership for a clinical-stage asset, it does not fit cleanly into the M\u0026A activity category (no acquisition, merger, or change of control) and is better classified as a material strategic collaboration that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:09.030521+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-26"}]}